At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Lovazadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of the Omega n3 Fatty on Human Platelet Function
In Brief
A Phase 2 clinical trial evaluating Lovaza for Cardiovascular Disease and Bleeding. Completed, enrolled 43 participants.
Detailed Summary
This study is to determine the effects of Lovaza in platelet function studies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease, Bleeding
Countries--
CollaboratorsReliant Pharmaceuticals
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartSep 2007
Primary CompletionJun 2009
TodayJul 2026
First PostedAug 13, 2007
Enrollment StartSep 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.9 years ago
Interventions
Lovazadrug
First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily